Across TCGA pan-cancer cohorts, TCN2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TCN2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TCN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TCN2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where TCN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.248	0.483	<.001	82	view →
LUAD	DFS	Tertile	II,III,IV	0.712	0.278	.005	9	view →
HNSC	OS	Median	II,III,IV	0.741	0.941	.012	5	view →
LSCC	OS	Median	III,IV	1.000	0.711	.004	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TCN2 tumor-vs-normal RNA expression · all TCN2 data types